{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T11:18:54Z","timestamp":1789730334826,"version":"4.0.1"},"reference-count":31,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2024,10,21]],"date-time":"2024-10-21T00:00:00Z","timestamp":1729468800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,10,21]],"date-time":"2024-10-21T00:00:00Z","timestamp":1729468800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Support Care Cancer"],"published-print":{"date-parts":[[2024,11]]},"DOI":"10.1007\/s00520-024-08934-0","type":"journal-article","created":{"date-parts":[[2024,10,21]],"date-time":"2024-10-21T04:02:51Z","timestamp":1729483371000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Multi-day vs single-day dexamethasone for the prophylaxis of chemotherapy-induced nausea and vomiting: systematic review and meta-analysis"],"prefix":"10.1007","volume":"32","author":[{"given":"Ronald","family":"Chow","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luigi","family":"Celio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James","family":"Im","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saverio","family":"Caini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lawson","family":"Eng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elizabeth","family":"Prsic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Florian","family":"Scott\u00e9","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matti","family":"Aapro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,10,21]]},"reference":[{"issue":"1","key":"8934_CR1","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s40266-021-00909-8","volume":"39","author":"J Herrstedt","year":"2022","unstructured":"Herrstedt J, Lindberg S, Petersen PC (2022) Prevention of chemotherapy-induced nausea and vomiting in the older patient: optimizing outcomes. Drugs Aging 39(1):1\u201321","journal-title":"Drugs Aging"},{"issue":"7","key":"8934_CR2","doi-asserted-by":"publisher","first-page":"3439","DOI":"10.1007\/s00520-020-05935-7","volume":"29","author":"R Chow","year":"2021","unstructured":"Chow R, Herrstedt J, Aapro M et al (2021) Olanzapine for the prophylaxis and rescue of chemotherapy-induced nausea and vomiting: a systematic review, meta-analysis, cumulative meta-analysis and fragility assessment of the literature. Support Care Cancer 29(7):3439\u20133459","journal-title":"Support Care Cancer"},{"issue":"2","key":"8934_CR3","doi-asserted-by":"publisher","first-page":"1015","DOI":"10.1007\/s00520-021-06606-x","volume":"30","author":"R Chow","year":"2022","unstructured":"Chow R, Navari RM, Terry B, DeAngelis C, Prsic EH (2022) Olanzapine 5 mg vs 10 mg for the prophylaxis of chemotherapy-induced nausea and vomiting: a network meta-analysis. Support Care Cancer 30(2):1015\u20131018","journal-title":"Support Care Cancer"},{"issue":"8","key":"8934_CR4","doi-asserted-by":"publisher","first-page":"2519","DOI":"10.1007\/s00520-018-4237-7","volume":"26","author":"R Chow","year":"2018","unstructured":"Chow R, Warr DG, Navari RM et al (2018) Should palonosetron be a preferred 5-HT3 receptor antagonist for chemotherapy-induced nausea and vomiting? An updated systematic review and meta-analysis. Support Care Cancer 26(8):2519\u20132549","journal-title":"Support Care Cancer"},{"issue":"8","key":"8934_CR5","doi-asserted-by":"publisher","first-page":"505","DOI":"10.1007\/s00520-023-07978-y","volume":"31","author":"R Chow","year":"2023","unstructured":"Chow R, Yin LB, Baqri W et al (2023) Prevalence and predictors of long-delayed (> 120 h) chemotherapy-induced nausea and vomiting (CINV)\u2014a systematic review and individual patient data meta-analysis. Support Care Cancer 31(8):505","journal-title":"Support Care Cancer"},{"key":"8934_CR6","doi-asserted-by":"publisher","first-page":"329","DOI":"10.3389\/fphar.2020.00329","volume":"11","author":"ASM Mosa","year":"2020","unstructured":"Mosa ASM, Hossain AM, Lavoie BJ, Yoo I (2020) Patient-related risk factors for chemotherapy-induced nausea and vomiting: a systematic review. Front Pharmacol 11:329","journal-title":"Front Pharmacol"},{"issue":"4","key":"8934_CR7","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1007\/s005200050078","volume":"5","author":"D Osoba","year":"1997","unstructured":"Osoba D, Zee B, Warr D, Latreille J, Kaizer L, Pater J (1997) Effect of postchemotherapy nausea and vomiting on health-related quality of life. The Quality of Life and Symptom Control Committees of the National Cancer Institute of Canada Clinical Trials Group. Support Care Cancer 5(4):307\u201313","journal-title":"Support Care Cancer"},{"issue":"24","key":"8934_CR8","doi-asserted-by":"publisher","first-page":"2782","DOI":"10.1200\/JCO.20.01296","volume":"38","author":"PJ Hesketh","year":"2020","unstructured":"Hesketh PJ, Kris MG, Basch E et al (2020) Antiemetics: ASCO guideline update. J Clin Oncol 38(24):2782\u20132797","journal-title":"J Clin Oncol"},{"issue":"2","key":"8934_CR9","doi-asserted-by":"publisher","first-page":"102195","DOI":"10.1016\/j.esmoop.2023.102195","volume":"9","author":"J Herrstedt","year":"2024","unstructured":"Herrstedt J, Clark-Snow R, Ruhlmann CH et al (2024) 2023 MASCC and ESMO guideline update for the prevention of chemotherapy- and radiotherapy-induced nausea and vomiting. ESMO Open 9(2):102195","journal-title":"ESMO Open"},{"issue":"1","key":"8934_CR10","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1007\/s00520-023-08221-4","volume":"32","author":"J Herrstedt","year":"2023","unstructured":"Herrstedt J, Celio L, Hesketh PJ et al (2023) 2023 updated MASCC\/ESMO consensus recommendations: prevention of nausea and vomiting following high-emetic-risk antineoplastic agents. Support Care Cancer 32(1):47","journal-title":"Support Care Cancer"},{"issue":"1","key":"8934_CR11","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1007\/s00520-023-08222-3","volume":"32","author":"F Scott\u00e9","year":"2023","unstructured":"Scott\u00e9 F, Schwartzberg L, Iihara H et al (2023) 2023 updated MASCC\/ESMO Consensus recommendations: prevention of nausea and vomiting following moderately emetic risk antineoplastic agents. Support Care Cancer 32(1):45","journal-title":"Support Care Cancer"},{"issue":"5","key":"8934_CR12","doi-asserted-by":"publisher","first-page":"589","DOI":"10.1007\/s00520-008-0535-9","volume":"17","author":"SM Grunberg","year":"2009","unstructured":"Grunberg SM, Dugan M, Muss H et al (2009) Effectiveness of a single-day three-drug regimen of dexamethasone, palonosetron, and aprepitant for the prevention of acute and delayed nausea and vomiting caused by moderately emetogenic chemotherapy. Support Care Cancer 17(5):589\u2013594","journal-title":"Support Care Cancer"},{"issue":"6","key":"8934_CR13","doi-asserted-by":"publisher","first-page":"895","DOI":"10.1038\/s41416-024-02611-z","volume":"130","author":"L Celio","year":"2024","unstructured":"Celio L, Antonuzzo A, Aapro MS (2024) Comment on \u201cDexamethasone-sparing on days 2\u20134 with combined palonosteron, neurokinin-1 receptor antagonist, and olanzapine in cisplatin: a randomized phase III trial (SPARED Trial). Br J Cancer 130(6):895\u2013896","journal-title":"Br J Cancer"},{"key":"8934_CR14","doi-asserted-by":"crossref","unstructured":"Chow R, Warr DG, Navari RM, et al (2018) Efficacy and safety of 1-day versus 3-day dexamethasone for the prophylaxis of chemotherapy-induced nausea and vomiting: a systematic review and meta-analysis of randomized controlled trials. J Hosp Manag Health Policy 2:25.\u00a0https:\/\/jhmhp.amegroups.org\/article\/view\/4296\/5093","DOI":"10.21037\/jhmhp.2018.04.05"},{"issue":"5","key":"8934_CR15","doi-asserted-by":"publisher","first-page":"1083","DOI":"10.1093\/annonc\/mdp584","volume":"21","author":"M Aapro","year":"2010","unstructured":"Aapro M, Fabi A, Nol\u00e8 F et al (2010) Double-blind, randomised, controlled study of the efficacy and tolerability of palonosetron plus dexamethasone for 1 day with or without dexamethasone on days 2 and 3 in the prevention of nausea and vomiting induced by moderately emetogenic chemotherapy. Ann Oncol 21(5):1083\u20131088","journal-title":"Ann Oncol"},{"issue":"8","key":"8934_CR16","doi-asserted-by":"publisher","first-page":"1217","DOI":"10.1007\/s00520-010-0941-7","volume":"19","author":"L Celio","year":"2011","unstructured":"Celio L, Frustaci S, Denaro A et al (2011) Palonosetron in combination with 1-day versus 3-day dexamethasone for prevention of nausea and vomiting following moderately emetogenic chemotherapy: a randomized, multicenter, phase III trial. Support Care Cancer 19(8):1217\u20131225","journal-title":"Support Care Cancer"},{"issue":"1","key":"8934_CR17","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1007\/s00520-023-08220-5","volume":"32","author":"K Jordan","year":"2023","unstructured":"Jordan K, Chan A, Gralla RJ et al (2023) Emetic risk classification and evaluation of the emetogenicity of antineoplastic agents\u2014updated MASCC\/ESMO consensus recommendation. Support Care Cancer 32(1):53","journal-title":"Support Care Cancer"},{"key":"8934_CR18","doi-asserted-by":"publisher","first-page":"l4898","DOI":"10.1136\/bmj.l4898","volume":"366","author":"JAC Sterne","year":"2019","unstructured":"Sterne JAC, Savovi\u0107 J, Page MJ et al (2019) RoB 2: a revised tool for assessing risk of bias in randomised trials. BMJ 366:l4898","journal-title":"BMJ"},{"issue":"3","key":"8934_CR19","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1016\/0197-2456(86)90046-2","volume":"7","author":"R DerSimonian","year":"1986","unstructured":"DerSimonian R, Laird N (1986) Meta-analysis in clinical trials. Control Clin Trials 7(3):177\u2013188","journal-title":"Control Clin Trials"},{"issue":"1","key":"8934_CR20","doi-asserted-by":"publisher","first-page":"15415","DOI":"10.1038\/s41598-020-72088-2","volume":"10","author":"J-C Trone","year":"2020","unstructured":"Trone J-C, Ollier E, Chapelle C et al (2020) Assessment of non-inferiority with meta-analysis: example of hypofractionated radiation therapy in breast and prostate cancer. Sci Rep 10(1):15415","journal-title":"Sci Rep"},{"key":"8934_CR21","doi-asserted-by":"publisher","unstructured":"Celio L, Bartsch R, Aapro M (2023) Dexamethasone-sparing regimens with NEPA (netupitant\/palonosetron) for the prevention of chemotherapy-induced nausea and vomiting in older patients (>65 years) fit for cisplatin: a sub-analysis from a phase 3 study. J Geriatr Oncol 14(6):101537.\u00a0https:\/\/doi.org\/10.1016\/j.jgo.2023.101537","DOI":"10.1016\/j.jgo.2023.101537"},{"key":"8934_CR22","doi-asserted-by":"publisher","first-page":"S1048","DOI":"10.1016\/j.annonc.2020.08.1462","volume":"31","author":"L Celio","year":"2020","unstructured":"Celio L, Cortinovis D, Cogoni A et al (2020) 1815MO Two simplified dexamethasone (DEX)-sparing regimens with NEPA for the prevention of emesis caused by cisplatin (DDP): a phase III, controlled, non-inferiority trial. Ann Oncol 31:S1048","journal-title":"Ann Oncol"},{"issue":"11","key":"8934_CR23","doi-asserted-by":"publisher","first-page":"3317","DOI":"10.1007\/s00520-015-2760-3","volume":"23","author":"N Furukawa","year":"2015","unstructured":"Furukawa N, Kanayama S, Tanase Y, Ito F (2015) Palonosetron in combination with 1-day versus 3-day dexamethasone to prevent nausea and vomiting in patients receiving paclitaxel and carboplatin. Support Care Cancer 23(11):3317\u20133322","journal-title":"Support Care Cancer"},{"issue":"10","key":"8934_CR24","doi-asserted-by":"publisher","first-page":"1000","DOI":"10.1200\/JCO.2017.74.4375","volume":"36","author":"Y Ito","year":"2018","unstructured":"Ito Y, Tsuda T, Minatogawa H et al (2018) Placebo-controlled, double-blinded phase III study comparing dexamethasone on day 1 with dexamethasone on days 1 to 3 with combined neurokinin-1 receptor antagonist and palonosetron in high-emetogenic chemotherapy. J Clin Oncol 36(10):1000\u20131006","journal-title":"J Clin Oncol"},{"issue":"7","key":"8934_CR25","doi-asserted-by":"publisher","first-page":"891","DOI":"10.1111\/cas.12675","volume":"106","author":"Y Komatsu","year":"2015","unstructured":"Komatsu Y, Okita K, Yuki S et al (2015) Open-label, randomized, comparative, phase III study on effects of reducing steroid use in combination with Palonosetron. Cancer Sci 106(7):891\u2013895","journal-title":"Cancer Sci"},{"issue":"3","key":"8934_CR26","doi-asserted-by":"publisher","first-page":"1405","DOI":"10.1007\/s00520-015-2905-4","volume":"24","author":"Y Kosaka","year":"2016","unstructured":"Kosaka Y, Tanino H, Sengoku N et al (2016) Phase II randomized, controlled trial of 1 day versus 3 days of dexamethasone combined with palonosetron and aprepitant to prevent nausea and vomiting in Japanese breast cancer patients receiving anthracycline-based chemotherapy. Support Care Cancer 24(3):1405\u20131411","journal-title":"Support Care Cancer"},{"issue":"10","key":"8934_CR27","doi-asserted-by":"publisher","first-page":"1607","DOI":"10.1111\/jog.12748","volume":"41","author":"M Matsuura","year":"2015","unstructured":"Matsuura M, Satohisa S, Teramoto M et al (2015) Palonosetron in combination with 1-day versus 3-day dexamethasone for prevention of nausea and vomiting following paclitaxel and carboplatin in patients with gynecologic cancers: a randomized, multicenter, phase-II trial. J Obstet Gynaecol Res 41(10):1607\u20131613","journal-title":"J Obstet Gynaecol Res"},{"issue":"2","key":"8934_CR28","doi-asserted-by":"publisher","first-page":"224","DOI":"10.1038\/s41416-023-02493-7","volume":"130","author":"H Minatogawa","year":"2024","unstructured":"Minatogawa H, Izawa N, Shimomura K et al (2024) Dexamethasone-sparing on days 2\u20134 with combined palonosetron, neurokinin-1 receptor antagonist, and olanzapine in cisplatin: a randomized phase III trial (SPARED Trial). Br J Cancer 130(2):224\u2013232","journal-title":"Br J Cancer"},{"issue":"1","key":"8934_CR29","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1007\/s10549-012-2205-3","volume":"136","author":"J Vardy","year":"2012","unstructured":"Vardy J, Pond G, Dodd A et al (2012) A randomized double-blind placebo-controlled cross-over trial of the impact on quality of life of continuing dexamethasone beyond 24 h following adjuvant chemotherapy for breast cancer. Breast Cancer Res Treat 136(1):143\u2013151","journal-title":"Breast Cancer Res Treat"},{"issue":"1","key":"8934_CR30","doi-asserted-by":"publisher","first-page":"1268","DOI":"10.1186\/s12885-019-6454-y","volume":"19","author":"L Celio","year":"2019","unstructured":"Celio L, Bonizzoni E, Zattarin E, Codega P, de Braud F, Aapro M (2019) Impact of dexamethasone-sparing regimens on delayed nausea caused by moderately or highly emetogenic chemotherapy: a meta-analysis of randomised evidence. BMC Cancer 19(1):1268","journal-title":"BMC Cancer"},{"issue":"1","key":"8934_CR31","first-page":"6650915","volume":"2023","author":"B Shahrami","year":"2023","unstructured":"Shahrami B, Biglari M, Kaveh-Ahangaran R, Rad S, Hadjibabaie M, Vaezi M (2023) Pharmacotherapy considerations in antiemetic prophylaxis for chemotherapy-induced nausea and vomiting. Eur J Cancer Care 2023(1):6650915","journal-title":"Eur J Cancer Care"}],"container-title":["Supportive Care in Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00520-024-08934-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00520-024-08934-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00520-024-08934-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,11,13]],"date-time":"2024-11-13T04:10:24Z","timestamp":1731471024000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00520-024-08934-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10,21]]},"references-count":31,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2024,11]]}},"alternative-id":["8934"],"URL":"https:\/\/doi.org\/10.1007\/s00520-024-08934-0","relation":{},"ISSN":["0941-4355","1433-7339"],"issn-type":[{"value":"0941-4355","type":"print"},{"value":"1433-7339","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,10,21]]},"assertion":[{"value":"11 June 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 October 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 October 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"736"}}